Please Note: This trial is no longer enrolling new participants
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
| Protocol No. | EA2165 | Scope | National |
|---|---|---|---|
| Principal Investigator | Patrick Loehrer | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
